WHO WE ARE →

WHAT WE DO →

OUR STORIES →

THE KIDNEY CANCER COMMUNITY →

SCIENTIFIC ADVISORS →

DONATE →

CONTACT →

Latest News

Leah Christoforidis: Rare Kidney Cancer and Her Advocacy for Research

Leah Christoforidis: Rare Kidney Cancer and Her Advocacy for Research

Meet Leah Christoforidis, a resilient Illinois resident and mother of four, whose life took an unexpected turn when diagnosed with a rare form of kidney cancer during her pregnancy. In this month's Community Spotlight, Leah shares her compelling journey from diagnosis to advocacy, revealing how...

SPRING ADVOCACY DAYS 2024 →

JOIN OUR COMMUNITY →

RAISING AWARENESS →

BE AN ADVOCATE →

DONATE NOW →

CONTACT →

Latest News

Leah Christoforidis: Rare Kidney Cancer and Her Advocacy for Research

Leah Christoforidis: Rare Kidney Cancer and Her Advocacy for Research

Meet Leah Christoforidis, a resilient Illinois resident and mother of four, whose life took an unexpected turn when diagnosed with a rare form of kidney cancer during her pregnancy. In this month's Community Spotlight, Leah shares her compelling journey from diagnosis to advocacy, revealing how...

KCRS: KIDNEY CANCER RESEARCH SUMMIT →

RESEARCH OPPORTUNITIES →

NEWS →

Latest News

Renée Maria Saliby: Kidney Cancer Research Champion

Renée Maria Saliby: Kidney Cancer Research Champion

Introducing Renée Maria Saliby, a dedicated young investigator in kidney cancer research! At just 27, Renée is blazing an inspring professional trail. Read on as she shares insights from her personal experiences and career pursuits, along with opportunities available for young researchers to...

SUPPORT OUR WORK →
ROCK THE RUN 2024 →
FUNDRAISE FOR KIDNEYCAN →
DONATE →
CONTACT →

Latest News

Leah Christoforidis: Rare Kidney Cancer and Her Advocacy for Research

Leah Christoforidis: Rare Kidney Cancer and Her Advocacy for Research

Meet Leah Christoforidis, a resilient Illinois resident and mother of four, whose life took an unexpected turn when diagnosed with a rare form of kidney cancer during her pregnancy. In this month's Community Spotlight, Leah shares her compelling journey from diagnosis to advocacy, revealing how...

Checkmate 9ER: A New Arrow in Our Quiver

The results of Phase 3 Checkmate 9ER trial are in! The 9ER trial evaluated the combination of Nivolumab (“Nivo”) and Cabozantinib (“Cabo”). This trial compared the combo to Sunitinib (“Sutent”) in patients who had not previously been on a drug and who had disease that had spread or metastasized.

Nivo is an immunotherapy agent that helps your immune system recognize and mobilize your T-cells to attack the cancer cells. Cabo is a TKI (tyrosine kinase inhibition) drug. The combo improved progression free survival (PFS), meaning the cancer did not progress as quickly compared to the other drug. It also improved OS (overall survival) in patients previously untreated. There were 651 patients in the trial. Nivo and Cabo are each approved by the FDA. This new combo is not yet approved, but will likely be approved in the near future. Other good news is that patient’s toxicity to the drug combo and their quality of life was improved. As soon as this combination is approved, it will give patients another option in their arsenal to battle mRCC.

Read the 2020 ESMO News Release here.